Novo Nordisk posts Q3 sales of obesity drug Wegovy above forecast
Novo Nordisk on Wednesday reported better-than-expected quarterly sales of its popular Wegovy weight-loss drug and narrowed its 2024 outlook for the year, in a mixed set of results reflecting growing competition in the fast-growing obesity drug market.
Novo Nordisk’s Wegovy sales jump on international rollouts
Novo’s obesity drug sales nearly doubled outside the U.S. during the quarter as global demand continued to rise.
Novo Nordisk’s Wegovy Sales Surge on Crucial US Market
Novo Nordisk A/S’s sales of the blockbuster weight-loss drug Wegovy leapt in the third quarter, a potential relief for investors after rival Eli Lilly & Co. reported disappointing obesity sales last week.
Novo Nordisk's quarterly Wegovy sales beat forecast, shares rise
Novo Nordisk reported on Wednesday better-than-expected quarterly sales of its popular Wegovy weight-loss drug, reassuring investors worried the drugmaker was losing its lead in the fast-growing obesity drug market to U.
Novo Nordisk’s Blockbuster Wegovy Sales Beat Expectations
The company narrowed its full-year guidance as its blockbuster weight-loss drug soars in popularity.
Novo Nordisk quarterly profit meets expectations as Wegovy maker narrows full-year guidance
Novo Nordisk on Wednesday reported third quarter earnings broadly in line with expectations and narrowed its 2024 full-year growth guidance.
Americans seeking Eli Lilly and Novo Nordisk’s weight-loss drugs turn to compounded market
An injection pen of Zepbound, Eli Lilly’s weight-loss drug ... Lilly last week reported a rare $1.5 billion sales ...
STAT2h
Novo’s earnings report sends shares up, as obesity drug sales show continued growth
Novo Nordisk shares were up Wednesday following an earnings report that showed continued sales growth of its obesity drug.
BioPharma Dive6d
Lilly shares fall as obesity drug sales miss forecasts
Third quarter Mounjaro and Zepbound sales, while up substantially versus the same period last year, grew little compared to ...
This Pharma Stock Is Rising. The Weight-Loss Drugs Race Has Widened Beyond Lilly, Novo.
Viking said that an early-stage study of its obesity pill VK2735 showed adults on the highest dosage lost 8.2% of their body ...
STAT12d
Eli Lilly weight loss drug shortage underscores deeper issues with FDA oversight
A turbulent series of events around the supply of Eli Lilly’s blockbuster weight loss treatment has raised concerns around ...
Lilly Cuts Outlook After Obesity Drug Sales Post First Miss
Eli Lilly & Co. lowered its full-year guidance Wednesday after sales of its blockbuster weight-loss drug fell short of expectations, which the company blamed on inventory issues.Most Read from Bloombe ...
Eli Lilly Stock Tumbles After Disappointing Obesity Drug Sales
Eli Lilly shares slid in premarket trading after the drugmaker reported disappointing quarterly results, with sales of its popular diabetes and anti-obesity drugs lower than expected. Lilly said inven ...
Novo Nordisk maintains booming sales of obesity and diabetes drugs
The Danish company’s share price rise of 7 per cent this year lags far behind its rival Eli Lilly’s 36 per cent, as the US company has gradually increased its share of the obesity and diabetes market ...
Viking Therapeutics surges after presenting ‘promising’ obesity drug data
Viking Therapeutics (VKTX) presented at the ObesityWeek meeting on Sunday, noting “promising” early results for its experimental ...
Wall Street Journal6d
Eli Lilly’s Bad Quarter Doesn’t Change Long-Term Math on Obesity Bonanza
Sales of GLP-1 drugs Mounjaro and Zepbound disappointed investors. (Shelby Knowles/Bloomberg News) Eli Lilly had a bad ...
Why Eli Lilly Is a No-Brainer Stock to Buy on the Dip
Here's why Eli Lilly is a no-brainer stock to buy on the dip ... Q3 earnings call that wholesalers decreased their ...
As Race To Best 'Miracle' Obesity Drug Heats Up, Ozempic Maker Novo Nordisk Tests New Hybrid Drug That Can Reduce Weight Up To 25%
Novo's development chief, Martin Holst Lange, has shown optimism about the drug's promise, though he refrained from making ...